11results about How to "High binding activity" patented technology

The application discloses a nano antibody against Ebola virus VP40 protein and application thereof in Ebola virus detection, wherein the nano antibody against Ebola virus VP40 protein is a 3E07 antibody. The nano antibody against Ebola virus VP40 protein prepared by the application has the characteristics of high sensitivity and wide binding spectrum. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by 3E07 and 3F06 antibodies can efficiently detect VP40 proteins and virus-like particles of various Ebola virus subtypes such as Zaire, Sudan and Beni, wherein the detection sensitivity of the Ebola virus VP40 protein of Zaire type can reach 0.039 ng / mL, and the antibody combination has a wide application prospect in the diagnosis and pathogen detection of Ebola virus disease.

The application provides an antibody against B7H6 and application thereof, the antibody comprising heavy chain variable region CDR1, CDR2 and CDR3 sequences shown in the amino acid sequences of SEQ ID NO: 1, 2 and 3 respectively or having at least 95% identity with SEQ ID NO: 1, 2 and 3; and / or light chain variable region CDR1, CDR2 and CDR3 sequences shown in the amino acid sequences of SEQ ID NO: 4, 5 and 6 respectively or having at least 95% identity with 4, 5 and 6. The antibody of the embodiment of the application can be combined with human and monkey B7H6 proteins, and the bispecific antibody prepared by using the antibody has higher human and monkey B7H6 binding activity, and can effectively treat and / or prevent B7H6-mediated related diseases.

The present application belongs to the field of biological medicine, and relates to an antibody or antigen-binding fragment thereof specifically binding to TAG72 and use thereof. The antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2 and LCDR3. The anti-TAG72 specific antibody of the present application has good specific killing activity on target cells.

The application belongs to the technical field of biology and specifically relates to an anti-CD25 monoclonal antibody, a preparation method thereof and application thereof. The anti-CD25 monoclonal antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region VH comprises three complementarity determining regions, and the amino acid sequences are shown as SEQ ID NO: 1-3. The light chain variable region VL also comprises three complementarity determining regions, and the amino acid sequences are shown as SEQ ID NO: 4-6. The application further provides a preparation method of the anti-CD25 monoclonal antibody. The monoclonal antibody development method has the advantages of short time consumption, high throughput and high positive rate.

The present application provides an anti-CDH17 antibody or an antigen binding fragment thereof, which can be a bispecific antibody constructed. The anti-CDH17 antibody provided by the present application can specifically bind to CDH17 protein, has a relatively strong CDH17-expressing tumor cell killing effect, can be effectively internalized on CDH17-expressing tumor cells, and can be prepared into an ADC which can be effectively internalized on CDH17-expressing tumor cells and has high killing activity; in particular, compared with an antibody binding to a single epitope of CDH17, the bispecific antibody of the present application has more accurate and multi-dimensional antigen recognition ability and higher targeting.

The application discloses a specific antibody MR-34 targeting a coronavirus MERS-CoV spike protein RBD. Sequences of CDRs of the antibody are shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the application can specifically combine with the MERS-CoV spike protein RBD domain by containing the specific sequence of CDRs. The antibody provided by the application has high targeting property and high combining activity. The antibody prepared by the preparation method provided by the application has high purity and can be prepared in large quantities. Overall, the antibody of the application can be used for development and optimization of a MERS-CoV infection detection method.

The application discloses an anti-Western Nile virus neutralizing antibody WN-XH3 and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, has good binding activity with Western Nile virus E protein, and has strong virus neutralizing activity, thereby laying a foundation for diagnosis and treatment of Western Nile virus infection related diseases, development of a Western Nile virus infection related disease treatment drug and the like, and can be used as a candidate of a clinical anti-Western Nile virus drug, and has a good application prospect.

The application discloses a Gastrodia elata-Wolfberry extract as well as a preparation method and application thereof, and belongs to the field of traditional Chinese medicine. The preparation method of the Gastrodia elata-Wolfberry extract comprises the following steps: (1) mixing Gastrodia elata and Wolfberry, crushing into powder, sieving, and obtaining a mixture powder; (2) adding water and a compound enzyme I, performing enzymolysis extraction under high-intensity ultrasonic waves with a power of 900-1800 W, obtaining a first enzymolysis liquid, centrifuging, and obtaining a first supernatant; (3) adding a compound enzyme II, performing enzymolysis extraction under high-intensity ultrasonic waves with a power of 900-1800 W, obtaining a second enzymolysis liquid, centrifuging, and obtaining a Gastrodia elata-Wolfberry extract liquid; and (4) freeze-drying to obtain the Gastrodia elata-Wolfberry extract. The compound enzyme I and the compound enzyme II are used to perform double enzymolysis on the Gastrodia elata and the Wolfberry, and high-intensity ultrasonic waves with a power of 900-1800 W are used to assist in the enzymolysis process, so that the nutritional components and effective active components in the Gastrodia elata and the Wolfberry can be effectively extracted, the enzyme consumption is reduced, and the extraction time is shortened.

The present invention provides a polypeptide comprising a heavy chain variable region (VH) domain and a light chain variable region (VL) domain linked via a peptide linker, wherein the peptide linker comprises the amino acid sequence of SEQ ID NO: 1 or 2.

The application belongs to the technical field of molecular biology, and particularly relates to an anti-Trop2 nanobody and application thereof. The application provides an anti-Trop2 nanobody, and an amino acid sequence of the anti-Trop2 nanobody is SEQ ID NO. 4. The anti-Trop2 nanobody provided by the application has specific recognition and binding capacity, and application thereof is related to diagnosis and treatment of Trop2 related tumor diseases, basic medical research, biological research and the like, and has wide biological application and clinical application value.

This invention discloses a PTPσ_Ig1-3 fusion protein, its preparation method, and its applications, belonging to the field of genetic engineering. The recombinant fusion protein is obtained by adding an inducible peptide to the N-terminus of the PTPσ_Ig1-3 domain, and sequentially adding a TEV restriction site, GFP fluorescent protein, and a His tag to the C-terminus. The amino acid sequence of the PTPσ_Ig1-3 domain is shown in SEQ ID NO.1, the amino acid sequence of the inducible peptide is shown in SEQ ID NO.2, and the amino acid sequences of the TEV restriction site, GFP fluorescent protein, and His tag are shown in SEQ ID NO.3. Experimental verification showed that this recombinant fusion protein has significant binding activity with glycosaminoglycans such as heparin sodium and chondroitin sulfate, showing promising applications in the study of axonal injury and regeneration mechanisms and in drug delivery therapy.